Physician profile
Christopher T Dibble
NPI 1912955642
$6,532.20
in general payments reported to CMS, 2019-2025
33 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $98.45 · 2021: $263 · 2022: $738 · 2023: $1,825 · 2024: $1,749 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Travel and Lodging: $308 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.03 |
| Travel and Lodging | $308.41 |
| Education | $229.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,316.29 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $773.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $690.88 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.45 | 2019-2025 | Jardiance |
| Nuvasive, INC. | $308.41 | 2023 | Xlif |
| Astrazeneca Pharmaceuticals Lp | $286.22 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Abbott Laboratories | $251.19 | 2019-2025 | Mitraclip, Navitor, Cardiomems |
| Pfizer INC. | $251.16 | 2019-2025 | |
| Amgen INC. | $244.33 | 2019-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $231.26 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $211.02 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $187.68 | 2019-2025 | Impella |
| Scpharmaceuticals INC. | $141.27 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $136.80 | 2022-2025 | Onpattro |
| Depuy Synthes Sales INC. | $118.38 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $112.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $93.15 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $85.67 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $69.93 | 2022-2024 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.32 | 2019-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $48.10 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $45.99 | 2021-2023 | Lexiscan |
| Cardiva Medical, INC. | $43.13 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bridgebio Pharma, INC. | $40.39 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $37.02 | 2024 | |
| Glaxosmithkline, LLC. | $36.19 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $33.88 | 2019-2023 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $33.10 | 2024 | Arcalyst |
| Novo Nordisk INC | $29.12 | 2023 | |
| Lilly USA, LLC | $24.62 | 2025 | Zepbound |
| Amarin Pharma, INC. | $23.95 | 2020 | |
| Genzyme Corporation | $18.87 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.33 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dibble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.